Key TakeawaysEli Lilly & Co. on Friday announced that the release of its experimental Alzheimer's drug will be delayed as the Food and Drug Administration looks more closely at its Phase 3 trial results.The drug maker said it was surprised at the decision, and that approval of the treatment won't come until after the first quarter.The news lifted shares of Biogen Inc., which already has a rival Alzheimer's medicine on the market, while shares of Eli Lilly lost ground. Shares of Eli Lilly & Co. (LLY) were d ...

ToplineThe FDA has delayed a decision on whether it will approve donanemab, Eli Lilly’s closely watched new Alzheimer’s drug, despite promising study results that showed it could significantly slow cognitive and functional decline in early-symptomatic Alzheimer’s patients, the pharmaceutical company announced Friday.FILE - A sign for Eli Lilly & Co. stands outside their corporate headquarters in Indianapolis on ... [+] April 26, 2017. The popular diabetes treatment Mounjaro pushed Eli Lilly past fourth quar ...

Eli Lilly and Co (NYSE:LLY) stock is slipping today, after the U.S. Food & Drug Administration (FDA) delayed approving the drugmaker's Alzheimer’s drug, donanemab, which was expected to be approved this month, and called for an advisory panel. At last glance, LLY was down 1.7% at $766.79. LLY has consistently seen record highs in 2024, most recently hitting a Mar. 4 all-time peak of $800.78. The stock's 20-day moving average has guided the shares higher since the start of the year, and is capturing today's ...

Eli Lilly headquarters in Indianapolis, Indiana, US, on Wednesday, May 3, 2023. Eli Lilly & Co.'s shares climbed in early US trading after its experimental drug for Alzheimer's slowed the progress of the disease in a final-stage trial, paving the way for the company to apply for US approval.Eli Lilly said Friday that the Food and Drug Administration has pushed back its approval decision deadline for the drugmaker's experimental Alzheimer's treatment donanemab in a surprise move.The agency plans to call a la ...

INDIANAPOLIS, March 8, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) expects to convene a meeting of the Peripheral and Central Nervous System Drugs Advisory Committee (PCNS) to discuss the Phase 3 TRAILBLAZER-ALZ 2 trial, which evaluated the efficacy and safety of donanemab in early symptomatic Alzheimer's disease.  The FDA has informed Lilly it wants to further understand topics related to evaluating the safety and efficacy of donan ...

Successful investor Mario Gabelli attained billionaire status primarily by investing his and his client’s money. He became well-known in the 1980s for making successful picks in media and telecom sectors, and was named Morningstar’s “Portfolio Manager of the Year” in 1997 and received the “Money Manager of the Year” award from Institutional Investor in 2011. Also noteworthy is that Barron’s added him to its “All Star Century Team.” Given Gabelli’s great track record, monitoring his top stocks makes sense. M ...

A month has gone by since the last earnings report for Eli Lilly (LLY) . Shares have added about 7.5% in that time frame, outperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Lilly due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers. Q4 Earnings Beat, Mounjaro, Zepbound Drive SalesLilly reported ...

Novo Nordisk shares climbed 5% on Thursday morning, according to LSEG data, hitting a fresh record highs after the Danish pharmaceutical giant reported positive early trial data for a new experimental weight loss drug.The company told an investor meeting that the Phase I trial of its highly-anticipated obesity drug amycretin showed a 13.1% weight loss in participants after 12 weeks, according to Reuters. This reading eclipses the 6% loss recorded after a 12-week trial for the company's wildly popular obesit ...

Eli Lilly and Co (NYSE:LLY) Cowen's 44th Annual Health Care Conference March 6, 2024 9:10 AM ET Company Participants Anat Ashkenazi - EVP & CFO Andrew Adams - Vice President of New Therapeutic Modalities & Scientific Leader Conference Call Participants Stephen Scala - TD Cowen Anat Ashkenazi Thank you all for coming to listen to the Lilly’s story this morning, and hope I'm sure you've been tracking us for a while. And you've seen what we've shared on the earnings call, the great progress we've had last year ...

Eli Lilly and Co (NYSE:LLY) Cowen's 44th Annual Health Care Conference March 6, 2024 9:10 AM ET Company Participants Anat Ashkenazi - EVP & CFO Andrew Adams - Vice President of New Therapeutic Modalities & Scientific Leader Conference Call Participants Stephen Scala - TD Cowen Anat Ashkenazi Thank you all for coming to listen to the Lilly’s story this morning, and hope I'm sure you've been tracking us for a while. And you've seen what we've shared on the earnings call, the great progress we've had last year ...